Solicitation
Request of Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response · Sol. 75A50126R00001_RFP_NPIVS_27
Due in 26 days
AI summary Beta
Some details are in the notice's attachments, which this summary didn't read. Check the attachments on SAM.gov.
BARDA (the Biomedical Advanced Research and Development Authority, part of HHS) wants one or more contractors to keep supporting pandemic influenza vaccine countermeasures, including making antigens, adjuvants and vaccines. Only companies with proven influenza vaccine experience can qualify. Proposals are due October 30, 2026; the full details are in attachments 01-19.
Watch out for
- Mandatory qualification requirement. Only companies that hold a U.S. influenza vaccine license or have submitted a BLA for an influenza vaccine can get an award, which rules out most small businesses.
To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential
- Details only in attachments. The real instructions, evaluation factors and requirements are in attachments 01-19, which are not in the notice text.
Please see full solicitation details and proposal submission instructions detailed in attachments 01-19 of this notice.
- Need for FDA-grade data and facilities. Work includes manufacturing vaccines and submitting analytical, nonclinical, clinical and CMC data to FDA, which takes heavy regulated-industry capability.
support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data
Read from the notice text only.
Full brief
What they want
- Provide vaccine medical countermeasures such as vaccines, antigens and adjuvants for pandemic preparedness and response
- Produce antigen and vaccines against influenza virus or other viruses with pandemic potential as BARDA requires
- Produce antigens, adjuvants and/or vaccines to help improve influenza vaccines (where feasibility data exists)
- Generate and submit relevant data to FDA (analytical, nonclinical, clinical, and CMC data) to support rapid regulatory decisions and manufacturing readiness
- Provide all services, personnel, materials, equipment and facilities (U.S. facilities preferred)
- Place of performance
- Washington, DC, USA (as listed in SAM.gov; the notice also says U.S. facilities are preferred)
- Offers due
- 2026-10-30 at 5:00 PM (SAM.gov shows 2026-10-30T17:00:00-04:00)
What to include when you submit
- See attachments 01-19 for full solicitation details and proposal submission instructions
You must have
- Must produce vaccines against influenza and influenza strains with pandemic potential
the Offeror must produce vaccines against influenza and influenza strains with pandemic potential
- Must show successful influenza vaccine manufacturing experience by holding a U.S. influenza vaccine license
Holding a U.S. influenza vaccine license
- Or must have developed an influenza vaccine, shown by submitting a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine
Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine
Current contractor
The notice describes this as a continuation of the existing BARDA Vaccine MCM program, but names no incumbent.
Not in the notice text
- Contract type and contract length
- Estimated value or funding level
- Evaluation factors and award method
- How and where to submit proposals
- Page limits and required forms
- Number of awards expected
Is this a fit for your business?
Create a free accountFedReady checks notices like this against your business profile, tracks deadlines, and alerts you to new matches. Creating an account is free.
Key facts
- Response due
- Oct 30, 2026, 9:00 PM UTC
- Posted
- Aug 17, 2026
- Notice type
- Solicitation
- Solicitation
- 75A50126R00001_RFP_NPIVS_27
- Agency
- Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response
- Office
- Barda - Aspr / Daappo / Barda Dcma
- Set-aside
- No Set aside used
- NAICS
- 541714
- Product/service code
- AN12
- Business type
- Engineering, architecture & research
- Place of performance
- Washington, DC, 20024
- Contracting contact
- Laura SaddisonLaura.Saddison@hhs.gov
Full notice text from SAM.gov
BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods. Mandatory Qualification Requirements: To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by: 1. Holding a U.S. influenza vaccine license; or 2. Have developed an influenza vaccine as evidenced by: a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine Please see full solicitation details and proposal submission instructions detailed in attachments 01-19 of this notice.
Similar open opportunities
- FirefoxDARPA is looking for research approaches for its Firefox program, which aims to build non-invasive brain-computer interfaces using an optical system that records neural signals…
- ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening
- SURPASS Webinar and Proposers' Day Information
- Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
- UNifying Imaging with QUantum Entanglement (UNIQUE) Proposers' Day